TAMM41: A Protein with Potential as A Drug Target (G132001)

Target Name: TAMM41

NCBI ID: G132001

TAMM41

TAMM41: A Protein with Potential as A Drug Target

TAMM41 (TAMM41_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a member of the TAMM family of proteins, which are involved in the regulation of anaphylaxis-like reactions.

TAMM41 is unique because of its structure and function. It is a 21-kDa protein that contains a unique N-terminus that consists of a 25 amino acid residue. This N-terminus is involved in the formation of a hydrophobic domain that is able to interact with various signaling molecules, including serotonin and melatonin.

TAMM41 functions as a negative regulator of the immune response. It is able to inhibit the activity of T cells, which are a key component of the immune system. TAMM41 does this by interacting with the signaling molecule PD-L1. This interaction between TAMM41 and PD-L1 allows TAMM41 to prevent PD-L1 from binding to its N-terminus and inhibiting its signaling activity.

TAMM41 is also involved in the regulation of inflammation and fibrosis. It has been shown to play a role in the development of various diseases, including heart disease, liver disease, and neurodegenerative diseases.

Despite its involvement in a number of important biological processes, TAMM41 is not yet a drug target or biomarker. There is ongoing research into the potential uses of TAMM41 as a drug target, particularly for the treatment of autoimmune diseases and other conditions that involve the regulation of the immune response.

One approach to targeting TAMM41 is to use small molecules to modulate its activity. Researchers have identified a number of small molecules that are able to interact with TAMM41 and alter its function. These molecules include compounds that can inhibit the activity of PD-L1, as well as molecules that can alter the structure and function of TAMM41 itself.

Another approach to targeting TAMM41 is to use antibodies to block its function. Researchers have developed antibodies that are able to bind to TAMM41 and prevent it from interacting with PD-L1. These antibodies have the potential to be used in a variety of applications, including the treatment of autoimmune diseases and other conditions that involve the regulation of the immune response.

While TAMM41 is an interesting protein with potential as a drug target or biomarker, there is still much to be learned about its function and the potential uses of its research. Further studies are needed to fully understand the role of TAMM41 in biology and its potential as a therapeutic target.

Protein Name: TAM41 Mitochondrial Translocator Assembly And Maintenance Homolog

Functions: Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol

The "TAMM41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAMM41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets